On November 29, 2022 Genomic Vision (Paris:GV) (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, reported a collaboration with the Centre National de la Recherche Scientifique (CNRS), the French state research organization, to launch a four-year core scientific program with the Cancer Research Center of Marseille (CRCM) for the development of companion diagnostic tests using Genomic Vision’s TeloSizer application (Press release, Genomic Vision, NOV 29, 2022, View Source [SID1234624570]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Telomeres are repetitive nucleotide sequences that form the ends of linear chromosomes. TeloSizer allows for high precision measurement of telomere length and distribution to uncover links between telomere length and the onset and severity of diseases such as cancer and age-associated diseases.
Learn more about TeloSizer by visualizing the video: View Source
"Genomic Vision continues to apply its innovative technologies for the benefit of patients and this collaboration with CNRS is an important milestone. We are pioneering the use of telomere length as a disease biomarker and this will contribute to cancer research." said Thierry Huet, Ph.D., Research and Development Director of Genomic Vision. "Telomere instability is a well-known hallmark of cancer. With TeloSizer, we can accurately visualize and measure telomeres length."
Christophe Lachaud, Group Leader at CRCM, commented: "We are very excited to utilize Genomic Vision’s TeloSizer application to develop highly accurate companion tests that will benefit patients. TeloSizer offers greater accuracy and more information compared to other telomere measurement methods."
Vincent Geli, Deputy Director of CRCM expert in telomeres added: "TeloSizer will provide new information on individual telomere length and their distribution."
New tests will be developed as part of a four-year core scientific program collaboration set up between Genomic Vision and the CRCM and will utilize Genomic Vision’s DNA combing technology and TeloSizer application. The program will employ scientific teams across the institute and will examine telomere length heterogeneity across different samples to uncover novel leukemia-specific telomere characteristics. Actionable insights from the project will be used for the development of personalize medicine approaches based on telomere morphology.
This project is part of the CRCM/IPC project supported by the OPALE Carnot Institute, a preferred partner to the healthcare Industry for research and development of innovative solutions aimed at diagnostic, treatment and follow-up of patients with leukemia, the blood cancer with the highest mortality rate, but also the leading cancer in children.